Skip to main content
SpringerLink
Log in

Systemic Inflammation and the Dynamics of HDL Cholesterol–Associated Residual Cardiovascular Risk

  • Clinical Trial Report
  • Published:
Current Atherosclerosis Reports Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Fruchart JC, Sacks F, Hermans MP, et al. Executive statement, the residual risk reduction initiative: a call to action to reduce residual vascular risk in dyslipidemic patients. Diab Vasc Dis Res. 2008;5:319–35.

    Article  PubMed  Google Scholar 

  2. Barter P, Gotto AM, LaRosa JC, et al. HDL-cholesterol, very low levels of LDL-cholesterol, and cardiovascular events. N Engl J Med. 2007;357:1301–10.

    Article  PubMed  CAS  Google Scholar 

  3. Rosenson RS. Low high-density lipoprotein cholesterol and cardiovascular disease: risk reduction with statin therapy. Am Heart J. 2006;151:556–63.

    Article  PubMed  CAS  Google Scholar 

  4. West of Scotland Coronary Prevention Study Group. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation. 1998;97:1440–5.

    Google Scholar 

  5. Ridker PM, Gesest J, Boekholdt SM, et al. HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial. Lancet. 2010;376:333–9.

    Article  PubMed  CAS  Google Scholar 

  6. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–207.

    Article  PubMed  CAS  Google Scholar 

  7. Ray KK, Cannon CP, Cairns R, Morrow DA, Ridker PM, Braunwald E. Prognostic utility of apoB/AI, total cholesterol/HDL, non-HDL-cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes: results from PROVE-IT TIMI 22. Arterioscler Thromb Vasc Biol. 2009;29:424–30.

    Article  PubMed  CAS  Google Scholar 

  8. Seeger JD, Walker AM, Williams PL, Saperia GM, Sacks FM. A propensity score-matched cohort study of the effect of statins, mainly fluvastatin, on the occurrence of acute myocardial infarction. Am J Cardiol. 2003;92:1447–51.

    Article  PubMed  CAS  Google Scholar 

  9. Rosenson RS, Davidson MH, Pourfazib R. Underappreciated opportunities for low-density lipoprotein management in patients with cardiometabolic risk. Atherosclerosis. 2010;213:1–7.

    Article  PubMed  CAS  Google Scholar 

  10. Rosenson RS, Otvos JD, Hsia J. Effects of rosuvastatin and atorvastatin on low-density and high-density lipoprotein particle concentrations in patients with metabolic syndrome: a randomized, double-blind, controlled study. Diabetes Care. 2009;32:1087–91.

    Article  PubMed  CAS  Google Scholar 

  11. Gotto AM, Whitney E, Stein EA, et al. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Circulation. 2000;101:477–84.

    PubMed  CAS  Google Scholar 

  12. Otvos JD, Collins D, Freedman DS, et al. Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial. Circulation. 2006;113:1556–63.

    Article  PubMed  CAS  Google Scholar 

  13. Vaiser T, Pennathur S, Greene PS, et al. Shotgun proteomics implicates protease inhibition and complement activation in the anti-inflammatory properties of HDL. J Clin Invest. 2007;117:595–8.

    Article  Google Scholar 

  14. Rosenson RS. Functional assessment of HDL: Moving beyond static measures for risk assessment. Cardiovas Drugs Ther. 2010;24:71–5.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Mount Sinai Heart, Mount Sinai School of Medicine, One Gustave L. Levy Place, Box 1031, New York, NY, 10029, USA

    Robert S. Rosenson

Authors
  1. Robert S. Rosenson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Robert S. Rosenson.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rosenson, R.S. Systemic Inflammation and the Dynamics of HDL Cholesterol–Associated Residual Cardiovascular Risk. Curr Atheroscler Rep 13, 187–189 (2011). https://doi.org/10.1007/s11883-011-0167-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11883-011-0167-2

Keywords

Search

Navigation